Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.5
4.4
Journals
Nanomaterials
Special Issues
Advances in Pharmaceutical Applications of Lipid-Based Nanoparticles
share announcement

Advances in Pharmaceutical Applications of Lipid-Based Nanoparticles

A special issue of Nanomaterials (ISSN 2079-4991). This special issue belongs to the section "Biology and Medicines".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 7463

Special Issue Editor

Dr. Angelina Angelova

E-Mail Website
Guest Editor
CNRS UMR 8612 "Institut Galien Paris-Saclay", Paris-Saclay University, F-91400 Orsay, France
Interests: lipid/protein nanoassemblies; liquid crystalline phases; cubosomes; self-assembled nanostructures and nanoparticles with neuroprotective properties; nanomedicine; nanocarriers for macromolecular drug delivery; membrane receptor nanoscale organization; lipids; peptides; proteins; BDNF; cyclodextrin; soft nanomaterials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Lipid-based nanomaterials and nanoparticles have gained considerable interest in vaccine development, targeted drug delivery, diagnostic imaging, and nanomedicine. They offer possibilities for the encapsulation of both hydrophilic and hydrophobic bioactive guest molecules in nanoscale reservoirs for controlled drug release. Lipid-based nanoparticles represent safe systems for the nanoformulation of mRNA, antimicrobial peptides, protein drugs, anti-viral, anti-inflammatory and anticancer agents, as well as for the delivery of nonviral gene-editing CRISPR-Cas9 complexes.

This Special Issue of Nanomaterials will focus on recent advances and ongoing cutting-edge research in the development of lipid nanoparticles (LNPs), liquid crystalline nanocarriers (cubosomes, spongosomes, hexosomes, and liposomes), nanostructured lipid carriers, solid lipid nanoparticles, and lipid–drug conjugates for potential new applications. The uses of LNPs and lipid-based nanomaterials as mono- and multidrug sustained delivery systems and their therapeutic uses in anti-viral therapies, cardioprotection, regenerative nanomedicine, slowing down of neurodegenerative disorders, and treatment of cancer, inflammation and infection diseases will be highlighted, among other possible applications. The preclinical and clinical status and the future prospects for lipid nanoparticle uses in diagnostics imaging, topical, intranasal, oral, and parenteral drug delivery as well as brain targeting will be considered. Remarkable attention will be given to the role of nanoparticle architectures and surface modifications in their cellular uptake mechanism.

Dr. Angelina Angelova
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lipid nanoparticles (LNPs)
  • liposomes
  • liquid crystalline nanocarriers
  • nanostructured lipid carriers
  • anti-viral therapeutics
  • mRNA therapeutics
  • siRNA therapeutics
  • protein therapeutics
  • peptide therapeutics
  • CRISPR-Cas9 delivery
  • controlled drug release
  • drug–lipid conjugates
  • lipids in therapy
  • intranasal delivery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 2310 KiB  
Article
Physiochemical Characterization of Lipidic Nanoformulations Encapsulating the Antifungal Drug Natamycin
by Luigi Talarico, Ilaria Clemente, Alessandro Gennari, Giulia Gabbricci, Simone Pepi, Gemma Leone, Claudia Bonechi, Claudio Rossi, Simone Luca Mattioli, Nicola Detta and Agnese Magnani
Nanomaterials 2024, 14(8), 726; https://doi.org/10.3390/nano14080726 - 20 Apr 2024
Cited by 1 | Viewed by 1727
Abstract
Natamycin is a tetraene polyene that exploits its antifungal properties by irreversibly binding components of fungal cell walls, blocking the growth of infections. However, topical ocular treatments with natamycin require frequent application due to the low ability of this molecule to permeate the [...] Read more.
Natamycin is a tetraene polyene that exploits its antifungal properties by irreversibly binding components of fungal cell walls, blocking the growth of infections. However, topical ocular treatments with natamycin require frequent application due to the low ability of this molecule to permeate the ocular membrane. This limitation has limited the use of natamycin as an antimycotic drug, despite it being one of the most powerful known antimycotic agents. In this work, different lipidic nanoformulations consisting of transethosomes or lipid nanoparticles containing natamycin are proposed as carriers for optical topical administration. Size, stability and zeta potential were characterized via dynamic light scattering, the supramolecular structure was investigated via small- and wide-angle X-ray scattering and 1H-NMR, and the encapsulation efficiencies of the four proposed formulations were determined via HPLC-DAD. Full article
(This article belongs to the Special Issue Advances in Pharmaceutical Applications of Lipid-Based Nanoparticles)
►▼ Show Figures

Figure 1

Review

Jump to: Research

35 pages, 1386 KiB  
Review
Engineered and Mimicked Extracellular Nanovesicles for Therapeutic Delivery
by Verena Poinsot, Nathalie Pizzinat and Varravaddheay Ong-Meang
Nanomaterials 2024, 14(7), 639; https://doi.org/10.3390/nano14070639 - 6 Apr 2024
Cited by 4 | Viewed by 2029
Abstract
Exosomes are spherical extracellular nanovesicles with an endosomal origin and unilamellar lipid-bilayer structure with sizes ranging from 30 to 100 nm. They contain a large range of proteins, lipids, and nucleic acid species, depending on the state and origin of the extracellular vesicle [...] Read more.
Exosomes are spherical extracellular nanovesicles with an endosomal origin and unilamellar lipid-bilayer structure with sizes ranging from 30 to 100 nm. They contain a large range of proteins, lipids, and nucleic acid species, depending on the state and origin of the extracellular vesicle (EV)-secreting cell. EVs’ function is to encapsulate part of the EV-producing cell content, to transport it through biological fluids to a targeted recipient, and to deliver their cargos specifically within the aimed recipient cells. Therefore, exosomes are considered to be potential biological drug-delivery systems that can stably deliver their cargo into targeted cells. Various cell-derived exosomes are produced for medical issues, but their use for therapeutic purposes still faces several problems. Some of these difficulties can be avoided by resorting to hemisynthetic approaches. We highlight here the uses of alternative exosome-mimes involving cell-membrane coatings on artificial nanocarriers or the hybridization between exosomes and liposomes. We also detail the drug-loading strategies deployed to make them drug-carrier systems and summarize the ongoing clinical trials involving exosomes or exosome-like structures. Finally, we summarize the open questions before considering exosome-like disposals for confident therapeutic delivery. Full article
(This article belongs to the Special Issue Advances in Pharmaceutical Applications of Lipid-Based Nanoparticles)
►▼ Show Figures

Figure 1

30 pages, 10706 KiB  
Review
Recent Uses of Lipid Nanoparticles, Cell-Penetrating and Bioactive Peptides for the Development of Brain-Targeted Nanomedicines against Neurodegenerative Disorders
by Yu Wu and Angelina Angelova
Nanomaterials 2023, 13(23), 3004; https://doi.org/10.3390/nano13233004 - 23 Nov 2023
Cited by 11 | Viewed by 3108
Abstract
The lack of effective treatments for neurodegenerative diseases (NDs) is an important current concern. Lipid nanoparticles can deliver innovative combinations of active molecules to target the various mechanisms of neurodegeneration. A significant challenge in delivering drugs to the brain for ND treatment is [...] Read more.
The lack of effective treatments for neurodegenerative diseases (NDs) is an important current concern. Lipid nanoparticles can deliver innovative combinations of active molecules to target the various mechanisms of neurodegeneration. A significant challenge in delivering drugs to the brain for ND treatment is associated with the blood–brain barrier, which limits the effectiveness of conventional drug administration. Current strategies utilizing lipid nanoparticles and cell-penetrating peptides, characterized by various uptake mechanisms, have the potential to extend the residence time and bioavailability of encapsulated drugs. Additionally, bioactive molecules with neurotropic or neuroprotective properties can be delivered to potentially mediate the ND targeting pathways, e.g., neurotrophin deficiency, impaired lipid metabolism, mitochondrial dysfunction, endoplasmic reticulum stress, accumulation of misfolded proteins or peptide fragments, toxic protein aggregates, oxidative stress damage, and neuroinflammation. This review discusses recent advancements in lipid nanoparticles and CPPs in view of the integration of these two approaches into nanomedicine development and dual-targeted nanoparticulate systems for brain delivery in neurodegenerative disorders. Full article
(This article belongs to the Special Issue Advances in Pharmaceutical Applications of Lipid-Based Nanoparticles)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop